Corcept Therapeutics — Third Quarter 2026 Earnings Summary

Corcept Therapeutics reported third-quarter 2026 revenue of $340.5 million, representing a 64 percent increase compared to the same period in 2025, driven by strong sales of Korlym and the newly launched Lifyorli. The company achieved net income of $126.8 million, or $1.01 per diluted share, and increased its cash and investments balance to $662.3 million. Clinical updates highlighted positive Phase 2 results for Lifyorli in platinum-resistant ovarian cancer and promising data for miricorilant in MASH and dazucorilant in ALS. Corcept reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion while advancing multiple late-stage clinical trials.